 PRINCETON, N.J.--BUSINESS WIRE--UroGen Pharma Ltd. Nasdaq: URGN, a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2021 financial results on Thursday, March 10, 2022, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. Audio Webcast The webcast will be made ava 